Major US bank shoots way above Novo Nordisk's own goals: New obesity drug will sell for almost USD 3.5bn in 2025.

US banking giant J.P. Morgan forecasts that Novo Nordisk will have increased its obesity business more than fourfold by 2025. Novo Nordisk aspires to more than double the business leg.

Novo Nordisk President and CEO Lars Fruergaard Jørgensen | Photo: Stine Bidstrup/ERH

Novo Nordisk's aspirations to more than double its obesity business by 2025 is way off the mark, according to major US bank J.P. Morgan.

The US analysts, led by Richard Vosser, are confident Novo Nordisk will turn the obesity drug Wegovy into a blockbuster – that is, a drug selling for more than USD 1bn – already next year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs